Literature DB >> 12765483

Evaluation of the role of MHC class II alleles, haplotypes and selected amino acid sequences in primary sclerosing cholangitis.

Peter T Donaldson1, Suzanne Norris.   

Abstract

BACKGROUND AND AIMS: Genetic susceptibility to primary sclerosing cholangitis is associated with several different HLA haplotypes, though a single "shared" susceptibility allele has yet to be identified. Most recently, attention has focussed on the MICA alleles in close proximity to the HLA class I, B locus. However, although there are strong associations with MICA*008, implicating this or a closely linked allele as major risk factors, this explanation alone does not account for all of the MHC-encoded susceptibility and resistance to PSC. The present study re-examines HLA class II associations in a large single centre series of well-characterised PSC patients. The specific aims of the study were to test existing associations and to develop hypotheses which together may account for all, or the majority, of the MHC-encoded susceptibility in PSC.
METHODS: A total of 148 adult white northern European patients and 134 control subjects were studied. HLA DRB1, DQA1, DQB1 alleles and DRB1*04, DRB1*13 and DRB3 subtypes were determined by standard PCR-genotyping.
RESULTS: The primary associations with the DRB3*0101--DRB1*0301--DQA1*0501--DQB1*0201 and DRB1*1301--DQA1*0103--DQB1*0603 haplotypes were confirmed (O.R. = 2.69, p < 0.0000025 and O.R. = 3.8, p < 0.0005). In addition the strong protective influence of the DRB1*04--DQB1*0302 haplotype was reaffirmed (O.R. = 0.26, p < 0.000025) and a previously unreported negative (i.e. protective) association with the DRB1*0701--DQB1*0303 haplotype was also demonstrated (O.R. = 0.15, p < 0.005). Further analysis suggested that susceptibility/resistance encoded by the second and third susceptibility haplotypes and by the two resistance haplotypes may be determined by specific amino acids at DQbeta-87 and DQbeta-55, respectively.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12765483     DOI: 10.1080/0891693021000054093

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  18 in total

Review 1.  Genetics of liver disease: immunogenetics and disease pathogenesis.

Authors:  P T Donaldson
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

2.  Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: unique clinical and human leukocyte antigen associations.

Authors:  Christopher L Bowlus; Chin-Shang Li; Tom H Karlsen; Benedicte A Lie; Carlo Selmi
Journal:  Liver Transpl       Date:  2010-11       Impact factor: 5.799

Review 3.  Genetic epidemiology of primary sclerosing cholangitis.

Authors:  Tom-H Karlsen; Erik Schrumpf; Kirsten-Muri Boberg
Journal:  World J Gastroenterol       Date:  2007-11-07       Impact factor: 5.742

4.  HLA haplotypes in primary sclerosing cholangitis patients of admixed and non-European ancestry.

Authors:  E K K Henriksen; M K Viken; M Wittig; K Holm; T Folseraas; S Mucha; E Melum; J R Hov; K N Lazaridis; B D Juran; O Chazouillères; M Färkkilä; D N Gotthardt; P Invernizzi; M Carbone; G M Hirschfield; S M Rushbrook; E Goode; C Y Ponsioen; R K Weersma; B Eksteen; K K Yimam; S C Gordon; D Goldberg; L Yu; C L Bowlus; A Franke; B A Lie; T H Karlsen
Journal:  HLA       Date:  2017-07-11       Impact factor: 4.513

Review 5.  Overlap syndromes of cholestatic liver diseases and auto-immune hepatitis.

Authors:  Christoph Schramm; Ansgar W Lohse
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

Review 6.  Mechanisms of tissue injury in autoimmune liver diseases.

Authors:  Evaggelia Liaskou; Gideon M Hirschfield; M Eric Gershwin
Journal:  Semin Immunopathol       Date:  2014-08-01       Impact factor: 9.623

7.  Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease.

Authors:  Sigrid Naess; Einar Björnsson; Jarl A Anmarkrud; Said Al Mamari; Brian D Juran; Konstantinos N Lazaridis; Roger Chapman; Annika Bergquist; Espen Melum; Steven G E Marsh; Erik Schrumpf; Benedicte A Lie; Kirsten M Boberg; Tom H Karlsen; Johannes R Hov
Journal:  Liver Int       Date:  2014-03-07       Impact factor: 5.828

Review 8.  Primary sclerosing cholangitis--what is the difference between east and west?

Authors:  Ali Shorbagi; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2008-07-07       Impact factor: 5.742

9.  HLA DRB1*13 as a risk factor for type 1 autoimmune hepatitis in North American patients.

Authors:  Albert J Czaja; Herschel A Carpenter; S Breanndan Moore
Journal:  Dig Dis Sci       Date:  2007-05-18       Impact factor: 3.199

10.  Human leucocyte antigens and pediatric autoimmune liver disease: diagnosis and prognosis.

Authors:  Norman Junge; Miriam Tiedau; Murielle Verboom; Michael Hallensleben; Rainer Blasczyk; Jerome Schlue; Imeke Goldschmidt; Eva-Doreen Pfister; Ulrich Baumann
Journal:  Eur J Pediatr       Date:  2015-11-14       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.